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Abstract
Cationic liposome-mediated intracellular delivery of a fluorescein-labeled chimeric DNA–RNA ribozyme targeted to the
HIV-1 5X LTR was investigated, using THP-1, THP-1rHIV-1 IIIB or HeLarLAV cells. Different fluorescence patterns were
observed when the cells were exposed to Lipofectamine, Lipofectin or DMRIE:DOPE Ž1:1. complexed to the ribozyme.
With Lipofectamine intense cell-associated fluorescence was found. Incubation with Lipofectin resulted in less intense
diffuse fluorescence, while with DMRIE an intense but sporadic fluorescence was observed. Differentiated THP-1rHIV-1 IIIB
cells were more susceptible to killing by liposome–ribozyme complexes than THP-1 cells. Under non-cytotoxic conditions
Ža 4-h treatment. complexes of 5, 10 or 15 m M Lipofectin or DOTAP:DOPE Ž1:1. and ribozyme, at lipid:ribozyme ratios of
8:1 or 4:1, did not affect p24 production in THP-1rHIV-1 IIIB cells in spite of the intracellular accumulation of the
ribozyme. A 24-h exposure of THP-1rHIV-1 IIIB cells to 5 m M Lipofectin or DOTAP:DOPE Ž1:1. complexed with either
the functional or a modified control ribozyme reduced virus production by approximately 30%. Thus, the antiviral effect of
the liposome-complexed ribozyme was not sequence-specific. In contrast, the free ribozyme at a relatively high concentration inhibited virus production by 30%, while the control ribozyme was ineffective, indicating a sequence-specific effect.
Both Lipofectin and DOTAP complexed with ribozyme were toxic at 10 and 15 m M after a 24-h treatment. A 4-h treatment
of HeLarLAV cells with Lipofectin at 5, 10 or 15 m M was not toxic to the cells, but also did not inhibit p24 production. In
contrast, treatment of HeLa CD4q cells immediately after infection with HIV-1 IIIB at the same lipid concentrations and
lipid:ribozyme ratios was cytotoxic. Our results indicate that the delivery of functional ribozyme into cells by cationic
liposomes is an inefficient process and needs extensive improvement before it can be used in ex vivo and in vivo
applications. q 1998 Elsevier Science B.V. All rights reserved.
Keywords: Human immunodeficiency virus ŽHIV.; Ribozyme; Cationic liposome; THP-1 cell; HeLa CD4q cell

Abbreviations: DME-HG, Dulbecco’s Modified Eagle’s Medium, high glucose; FBS, heat-inactivated fetal bovine serum; DOPE,
dioleoylphosphatidylethanolamine; DMRIE, a 1:1 Žwrw. mixture of 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethyl ammonium
bromide ŽDMRIE. and DOPE; DOTAP, a 1:1 Žwrw. mixture of N-Ž1-Ž2,3-dioleoyloxy.propyl-N,N,N-trimethylammonium propane.
ŽDOTAP. and DOPE; LF, Lipofectin reagent; LFA, LipofectAMINEe reagent; PBS, phosphate-buffered saline; PMA, phorbol
12-myristate 13-acetate
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1. Introduction
Ribozymes Ž Rz. are RNA molecules capable of
catalytically cleaving specific phosphodiester bonds
in complementary RNA molecules w1–4x. When delivered intracellularly, they can interfere with both
pre-integration and post-integration events of the HIV
replication cycle, by cleaving incoming viral RNA
and transcribed mRNAs w5x. Delivery of Rz to cells
has been attempted by Ž i. endogenous expression of
the Rz-encoding gene or Žii. exogenous delivery of
chemically-synthesized Ž pre-formed. Rz targeted to
highly conserved regions of the virus w6x.
Chang et al. w7x have demonstrated that an antiHIV-1 gag Rz can be expressed under the control of
the constitutive human b-actin promoter in HeLa
CD4q cells. The stable expression of this anti-gag
Rz in HeLa CD4q cells reduces gag transcripts and
p24 levels upon infection with HIV-1 w1x. Since then,
many of the genetic elements of the retroviral genome
have been targeted including functional proteins,
leader sequences and regulatory protein sequences
w2,8x. A hairpin Rz designed to cleave HIV-1 RNA in
the 5X leader sequence suppresses virus expression in
HeLa cells cotransfected with proviral DNAs w9,10x.
Human T-cell lines, primary T cells and CD34q
hematopoietic stemrprogenitor cells transduced with
retroviral vectors containing Rz were shown to be
resistant to challenge with diverse strains of HIV-1,
including uncloned clinical isolates w11–16x.
A number of problems need to be addressed before
pre-formed Rz can be used successfully for therapy:
Ži. stabilization of the Rz against serum and cellular
nucleases without compromising its catalytic activity;
Žii. efficient delivery to the target cells; Žiii. intracellular localization of an active Rz; Ž iv. co-localization of the Rz with its mRNA target inside cells. In
contrast to endogenous expression, exogenous delivery permits the use of chemically modified Rz Ž MRz.
which are more resistant to degradation by nucleases,
while maintaining cleavage capability w17,18x.
Chimeric DNA–RNA hammerhead Rz, with DNA in
helices I and III, have an increased resistance to
nucleases and a six-fold greater catalytic activity than
an analogous all-RNA Rz w19x.
Several cationic liposome formulations have been
developed to facilitate delivery of DNA w20–23x,
mRNA w24x and antisense oligonucleotides into eu-

karyotic cells w25–30x. In the present study we evaluated the intracellular delivery and anti-HIV effect of
a fluorescein-labeled chimeric DNA–RNA Rz targeted to the HIV-1 5X LTR, using four cationic
liposomal preparations. Lipofectamine, Lipofectin,
and liposomes composed of either DMRIE:DOPE wŽa
1:1 Žwrw. mixture of 1,2-dimyristyloxypropyl-3-dimethyl-hydroxyethylammonium bromide ŽDMRIE.
and DOPE. :Ždioleoylphosphatidylethanolamine.x Ž 1:1,
wrw. or DOTAP:DOPE w N-Ž1-Ž2,3-dioleoyloxy.propyl-N, N, N-trimethylammonium propane.x Ž 1:1,
wrw., were complexed with the Rz and added to
cultures of differentiated monocytic THP-1 cells and
chronically infected THP-1rHIV-1 IIIB cells, as well
as chronically and de novo infected HeLa CD4q
cells. Differentiated THP-1 and THP-1rHIV-1 IIIB
cells were used in our study because they represent a
convenient model of monocyte-derived macrophages
w31x and chronically infected macrophages w32,33x,
respectively. Because HeLa cells are often used as a
model system for cationic liposome-mediated DNA
delivery, chronically infected HeLarLAV cells and
de novo infected HeLa CD4q cells were also included in our study. Some of our results have been
presented earlier in preliminary form w34,35x.

2. Materials and methods
2.1. Materials
LipofectAMINEe reagent and Lipofectin reagent
were obtained from GIBCO BRL Life Technologies,
ŽGaithersburg, MD.. LipofectAMINEe reagent w36x
contains the polycationic lipid 2,3-dioleyloxyN w 2 Ž sperminecarboxamido. ethyl x -N, N -dimethyl-1propanaminium trifluoroacetate Ž DOSPA. and the
neutral lipid, DOPE Ž 3:1, wrw.. Lipofectin reagent
w20x contains the monocationic lipid N-w1-Ž 2,3 dioleyloxy. -propylx-N,N,N-trimethylammonium chloride
ŽDOTMA. and DOPE Ž1:1, wrw. . DMRIE reagent
w37x was synthesized by VICAL ŽSan Diego, CA..
Small unilamellar liposomes composed of DOTAP
and DOPE Ž1:1, wrw. were prepared in our laboratory w38x. Alamar Blue dye was purchased from
Alamar Biosciences Ž Sacramento, CA. . DOTAP and
DOPE were obtained from Avanti Polar Lipids
ŽAlabaster, AL.. Penicillin, streptomycin and L-
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glutamine were obtained from Irvine Scientific Ž Santa
Ana, CA.. PBS was obtained from Zymed Laboratories ŽSouth San Francisco, CA. .
A 38-mer, 5X fluorescein-labeled, chimeric DNA–
RNA hammerhead Rz with two phosphorothioate
linkages at the 3X terminal Ž mol. wt. 12,519.2. , was
targeted to the HIV-1 5X LTR. The catalytic activity
of the Rz was first tested in a cell-free system. A
control Rz with a scrambled sequence in the binding
arms was also designed and synthesized Ž MRz. . The
sequences of these Rz are as follows:
Rz: 5X-ACACAACAcugaugaGTCCGTGAG GACgaaaCGGGC)A)C-3X
MRz: 5X-CAAACAACcugaugaGTCCGTGAGGACgaaaACCGG)G)C-3X
where the ‘)’ indicates a phosphorothioate internucleotide linkage, capital letters represent deoxyribonucleotides and lowercase letters represent ribonucleotides.
The mixed oligodeoxyribo- and ribonucleotides
were synthesized on an automated synthesizer ŽApplied Biosystems 394 RNArDNA. as described previously w19x.
2.2. Cells and Õirus
THP-1 cells were obtained from the American
Type Culture Collection ŽTIB-202.. A chronically
HIV-infected cell line Ž designated THP-1rHIV-1 IIIB .
was developed in our laboratory by infecting THP-1
cells with HIV-1 IIIB at a low multiplicity of infection
w31x, and the clone designated as THP-1r IIIB30 was
used in further experiments w39x. Cells were maintained at 378C, under 5% CO 2 in RPMI 1640 medium
supplemented with 10% Ž vrv. heat-inactivated FBS
Žfetal bovine serum. ŽSigma; St. Louis, MO.
ŽRPMIr10., penicillin Ž 100 unitsrml. , streptomycin
Ž100 m grml. and L-glutamine Ž2 mM. . The cells
were passaged 1:6 once a week.
HeLarLAV and HeLa CD4q were obtained
through the AIDS Research and Reference Reagent
Program ŽDivision of AIDS, NIAID, NIH, Bethesda,
MD. from Drs. Joerg Berg and Matthias Wabl w40x
and Dr. Richard Axel w41x, respectively. HeLarLAV
cells were maintained at 378C, under 5% CO 2 in
DME-HG ŽDulbecco’s Modified Eagle’s Medium,
high glucose. ŽIrvine Scientific. supplemented with
10% FBS ŽDMEr10. , penicillin Ž 100 unitsrml.,
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streptomycin Ž100 m grml. and L-glutamine Ž4 mM. .
HeLa CD4q cells were grown in RPMI 1640 medium
with 10% FBS, penicillin Ž100 unitsrml. , streptomycin Ž100 m grml., L-glutamine Ž2 mM. and 0.6
mgrml Geneticin Ž G418. sulfate ŽGIBCO.. The cells
were passaged 1:20 once a week. Flow cytometric
analysis indicated that over 90% of cells were CD4positive.
The presence of cell surface CD4 was examined
by direct immunofluorescence assay, using fluorescein isothiocyanate Ž FITC.-conjugated Leu3 antibody
ŽBecton-Dickinson., with FITC-conjugated mouse
IgG as a control. The fluorescence distribution was
analyzed with a fluorescence-activated cell sorter
ŽFACScan; Becton-Dickinson, Mountain View, CA. .
2.3. Treatment with liposome–Rz complexes
Uninfected monocytic THP-1 cells and chronically
infected THP-1rHIV-1 IIIB cells Ž1 ml at 1 = 10 6
cellsrml. were plated in 48-well plates, treated with
160 nM phorbol 12-myristate 13-acetate Ž PMA. w37x
for 24 h at 378C, and exposed to liposome–Rz complexes 5 or 6 days post-differentiation. HeLarLAV
cells were plated in 24-well plates Ž2 = 10 5 cellsr2
ml. and treated after 48 h, at ; 60% confluency, in
the absence or presence of 8% FBS.
LipofectAMINEe reagent ŽLFA. was provided at
0.5 mM Ž corresponding to 2 mgrml. and Lipofectin
reagent ŽLF. was provided at 0.68 mM Ž corresponding to 1 mgrml.. DMRIErDOPE Ž referred to as
DMRIE in the rest of the paper. was prepared to
0.747 mM in sterile water, corresponding to 1 mgrml.
DOTAPrDOPE Žreferred to as DOTAP. was prepared at 0.71 mM Ž corresponding to 1 mgrml..
Lyophilized fluorescent Rz was stored at 48C, dissolved in 10 mM Tris, 1 mM EDTA, 0.1 M NaCl
buffer, pH 8.0, and then diluted in the appropriate
medium without serum or antibiotics.
For all experiments, the indicated amounts of lipid
and Rz were complexed for 30 min at room temperature in RPMI or DME-HG medium without serum or
antibiotics. Meanwhile the cells were washed twice
with 1 ml medium, and 0.4 ml of medium was placed
on each well. The lipid–Rz mixture was then added
gently in a volume of 0.1 ml per well. The mixture
remained on the cells for 4 h or 24 h at 378C in a 5%
CO 2 incubator. Cells treated with either medium or
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Rz alone served as controls. Following treatment,
cells were washed with PBS and viewed by phase
contrast and fluorescence microscopy, using a Nikon
Diaphot microscope Ž Nikon Instrument Group;
Melville, NY. . Cell morphology was evaluated by
inverted phase contrast microscopy at 250 = or 400 =
magnification. Photographs of fluorescence and
phase-contrast fields were made on Fuji color print
film at ISO ŽASA. 1600 or on Kodak black and white
print film at ASA 400. The treated cells were fed
every 2–3 days with fresh medium Ž RPMIr10 for
THP-1 and HeLa CD4q cells, or DMEr10 for
HeLarLAV cells. and incubated for the indicated
periods of time before the Alamar Blue assays and
monitoring of the p24 level in supernatants. p24
values represent the amount of virus produced Ž in
ngrml. between the time of medium change and the
time of p24 determination. This time period is indicated in the figure legends. Results were compared to
medium-treated controls. Statistical significance was
evaluated by the unpaired Student’s t-test, using
StatView software ŽBrainPower, Calabasas, CA. . p
values of F 0.05 were taken to indicate a significant
difference.
2.4. HIV infection of HeLa CD4 q cells
The virus and infected cells were handled in a
BL-3 facility. HeLa CD4q cells were plated in 12well plates at 2 = 10 5 cellsrwell, and on the next
day, at ; 50% confluency, they were exposed to
HIV-1 IIIB for 2 h at 378C, at 5 = 10 3 TCID50 per
well. Following infection, the cells were washed to
remove unbound virus and were treated with liposome–Rz complexes or medium alone. Control cells
were treated similarly but not exposed to virus. The
infection was monitored by determining viral p24 in
culture supernatants by an antigen capture ELISA
assay w42x, using a Molecular Devices Ž Menlo Park,
CA. Vmax microplate reader.
The supernatant of chronically infected
H9rHTLV-IIIB cells was used as a source of the
HIV-1 strain, HIV-1 IIIB . The culture supernatants
were harvested at times of peak p24 production and
stored at y808C. The p24 concentration of the stock
was 1.4 m grml as determined by ELISA. The tissue
culture infectious dose, 50% endpoint Ž TCID50 . , was
determined as described by Johnson and Byington

w43x. The infectious titer per 1 m g p24 was 7.1 = 10 3
TCID50 .
2.5. Cell Õiability assay
The number of viable cells used for experiments
was determined by Trypan Blue exclusion. Cell viability after treatment with free or liposome-complexed Rz was quantified by a modified Alamar Blue
assay w44x. Briefly, 1.0 ml of 10% Žvrv. Alamar Blue
dye in the appropriate medium was added to each
well. After incubation for various times Ždescribed
under figure legends. at 378C, 200 m l of the supernatant was collected from each well and transferred
to 96-well plates. The absorbance at 570 nm and 600
nm was measured with a microplate reader. Cell
viability Žas a percentage of mock-treated control
cells. was calculated according to the formula, Ž A 570
y A 600 . of test cells = 100rŽ A 570 y A 600 . of control
cells. After removal of the Alamar Bluermedium
mixture, fresh growth medium was added, and cells
were returned to the incubator. Thus, the Alamar
Blue assay allows determination of viability over the
culture period without the detachment of adherent
cells. A good correlation was obtained between the
Alamar Blue assay and Trypan Blue staining w39x.
3. Results
3.1. DeliÕery of liposome–Rz complexes to uninfected, differentiated THP-1 cells
Differentiated THP-1 cells were exposed to the
liposome–Rz complexes for 4 or 24 h in RPMI
medium with 8% FBS. The cells were exposed to
Lipofectamine at 3 or 8 m M, and to Lipofectin and
DMRIE at 15 or 40 m M, complexed with Rz, at a
lipid:Rz Ž wrw. ratio of 1.3:1. Under these conditions, the charge ratio Žqry . for Lipofectamine
was 1.7, while for Lipofectin and DMRIE this ratio
was about 0.3. Thus, a net positive charge was not
absolutely required for the complex to be taken up.
Different fluorescence patterns were observed with
the three liposomal preparations. With Lipofectamine, intense cell-associated fluorescence was
found. Treatment with Lipofectin resulted in less
intense diffuse fluorescence, while with DMRIE, an
intense but sporadic fluorescence was observed Ž Figs.
1 and 2.. The Rz alone, at concentrations of 12 to 40
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Fig. 1. Fluorescence ŽA–D. and phase contrast ŽAX –DX . micrographs of differentiated uninfected THP-1 cells treated for 4 h with LFA at 3
m M ŽA. or 8 m M ŽB., and LF ŽC. or DMRIE ŽD. at 40 m M, complexed with Rz, at a lipid:Rz Žwrw. ratio of 1.3:1.
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Fig. 2. Fluorescence ŽA–D. and phase contrast ŽAX –DX . micrographs of differentiated uninfected THP-1 cells treated for 24 h with LFA at
3 m M ŽA. or 8 m M ŽB., and LF ŽC. or DMRIE ŽD. at 40 m M, complexed with Rz, at a lipid:Rz Žwrw. ratio of 1.3:1.
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At the ratio of 4:1, the cationic liposome–Rz complexes were not toxic and did not inhibit p24 production ŽFig. 4A..
Because transfection with Lipofectin resulted in
diffuse cytoplasmic fluorescence further experiments
were performed with this lipid as well as with its
analog DOTAP which has acyl instead of alkyl chains.
Differentiated THP-1rHIV-1 IIIB cells were treated
with Lipofectin or DOTAP at 5, 10 or 15 m M,
complexed with Rz, at a lipid:Rz Žwrw. ratio of 8:1
or 4:1, or Rz alone at 5.5 m grml Ž0.44 m M.. The
Fig. 3. Effect of LFA, LF or DMRIE complexed with Rz on the
viability of differentiated, uninfected THP-1 cells. PMA-treated
THP-1 cells, 5 days post-differentiation, were exposed to the
liposome–Rz complexes ŽLFA: Lipofectamine, LF: Lipofectin.
or the Rz alone Ž40 m grmls 3.2 m M. for 4 or 24 h Žsee Section
2 for details.. Cell viability was measured on day 13 for the 4-h
treatment, and on day 12 for the 24-h treatment, by incubating
the cells with Alamar Blue overnight at 378C. The viability is
expressed as percent of the control. Data represent the mean"
standard deviation obtained from duplicate wells.

m grml Ž0.96 to 3.2 m M., showed no significant
cellular accumulation Ž data not shown. . The cells
were further incubated and fed every 2–3 days with
RPMIr10 medium before cell viability was quantified on days 12 or 13 post-treatment. The only cytotoxic treatment was that with 8 m M Lipofectamine
which caused disintegration of the cells ŽFig. 3. .
3.2. DeliÕery of liposome–Rz complexes to differentiated THP-1r HIV-1IIIB cells
Differentiated THP-1rHIV-1 IIIB cells were exposed to Lipofectamine at 3 m M, and to Lipofectin
or DMRIE at 15 m M, complexed with Rz, at a
lipid:Rz Žwrw. ratio of 4:1 or 1.3:1. Micrographs
were taken following a 4-h treatment in RPMI
medium with 8% FBS. The fluorescence patterns
obtained with the three liposomal preparations were
similar to that described for differentiated THP-1
cells Ždata not shown. . The cells were further incubated and fed every 2 days with fresh RPMIr10
medium; viral p24 production was measured on days
2, 4, 6 and 8. Only 3 m M Lipofectamine was cytotoxic at the ratio of 1.3:1, causing disintegration of
the cells and inhibition of p24 production Ž Fig. 4B. .

Fig. 4. The effect of Rz, complexed with LFA Ž3 m M., LF or
DMRIE Žboth 15 m M., on p24 production in differentiated
THP-1rHIV-1 IIIB cells. Differentiated THP-1rHIV-1 IIIB cells in
48-well plates, 6 days post-differentiation, were exposed to the
liposome–Rz complexes ŽLFA: Lipofectamine, LF: Lipofectin.,
at lipidrRz ratios of 4:1 Žwrw. ŽA. or 1.3:1 ŽB., or the Rz alone
at 15 m grml Ž1.2 m M., for 4 h Žsee Section 2 for details.. Viral
p24 antigen production within the previous 48-h period was
determined on days 2, 4, 6 and 8. Data represent the mean"
standard deviation of p24 determinations in duplicate, in supernatants of duplicate wells Ž ns 4..
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charge ratio Žqry . for the 8:1 complex was 1.8
while for the 4:1 complex this ratio was 0.9. Following a 4 or 24-h treatment in RPMI medium with 8%
FBS, micrographs were taken. After a 4-h treatment,
p24 production was determined on days 3, 5, 7, 9 and
14, and cell viability was measured on day 14. After
a 24-h treatment, p24 production was determined on
days 2, 4 and 6, and cell viability was measured on
day 6. A concentration-dependent, cell-associated dif-

fuse fluorescence was observed after a 4-h treatment.
However, neither Lipofectin- nor DOTAP–Rz complexes reduced cell viability or affected p24 production after a 4-h treatment Ždata not shown. .
A 24-h exposure to 5 m M Lipofectin or DOTAP
complexed with Rz, at a lipid:Rz Žwrw. ratio of 8:1
or 4:1, reduced the p24 levels at day 2 Ž Fig. 6..
Fluorescence patterns observed with DOTAP are
shown in Fig. 5. At Lipofectin:Rz ratios of 8:1 or 4:1,

Fig. 5. Fluorescence ŽA–C. and phase contrast ŽAX –CX . micrographs of differentiated THP-1rHIV-1 IIIB cells treated with free Rz Ž5.5
m grml s 0.44 m M. ŽA., and 5 m M DOTAP at a lipid:Rz Žwrw. ratio of 8:1 ŽB. or 4:1 ŽC. for 24 h.

K. Konopka et al.r Biochimica et Biophysica Acta 1372 (1998) 55–68

Fig. 6. Effect of LF ŽA. or DOTAP ŽB. complexed with Rz on
p24 production in differentiated THP-1rHIV-1 IIIB cells. PMAtreated THP-1rHIV-1 IIIB cells, 6 days post-differentiation, were
exposed to the liposome–Rz complexes, at lipid:Rz ratios Žwrw.
of 8:1 or 4:1, or the Rz alone at 5.5 m grml Ž0.44 m M., for 24 h
Žsee Section 2 for details.. The p24 antigen production within the
previous 48-h period was measured on days 2 and 4. Data
represent the mean"standard deviation of p24 determinations in
duplicate, in supernatants of duplicate wells Ž ns 4. except in
controls which were measured in five wells. Asterisks Ž). indicate that the values were significantly different from the untreated controls. LF and DOTAP at 10 and 15 m M were cytotoxic.

the p24 levels were reduced by 32.5% or 39.4%,
respectively. These values were significantly lower
than the untreated controls Ž0.005 - p F 0.01, or p F
0.005, respectively. . With the DOTAP:Rz complex at
the ratio of 8:1 or 4:1, the p24 levels were reduced by
48.6% or 31.2%, respectively. These values were
significantly lower than the untreated controls Ž p F
0.005, or 0.005 - p F 0.01, respectively.. At this lipid
concentration Ž5 m M., the lipid:Rz ratio of 8:1 corresponds to 0.93 m g Rzrml Ž0.074 m M. and the 4:1
ratio corresponds to 1.9 m g Rzrml Ž0.15 m M.. When
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cells were treated for 24 h with free Rz, at 5.5
m grml Ž0.44 m M., the p24 level was reduced by
23.7% compared to untreated controls Ž0.01 - p F
0.025.. On day 4 and 6 the p24 values were significantly lower only with the Lipofectin:Rz complex at
the ratio of 4:1 ŽFig. 6A. Žday 6; data not shown. .
The p24 levels were reduced by 25.4% Ž 0.005 - p F
0.01. and 19.1% Ž0.025 - p F 0.05. on day 4 and 6,
respectively. Thus, on day 2 virus production was
reduced to a greater extent by the liposome-complexed Rz than by a three to six-fold higher concentration of free Rz. This concentration of free Rz
corresponded to the Rz added with lipid:Rz complex
at 15 m M lipid at the ratio 4:1. Therefore, liposomemediated delivery of the Rz enhanced its anti-HIV
effect, as determined by reduction of p24 levels on
day 2. However, treatment with the Lipofectin:Rz
Ž8:1. and DOTAP:Rz Ž8:1 and 4:1. complexes could
not prevent virus production from increasing over
time. On days 4 and 6, the level of p24 antigen
produced within the previous 48-h period was similar
in the treated and control wells. Under the same
conditions, both liposomal preparations at 10 and 15
m M were highly cytotoxic, causing substantial disintegration of the cells Ždata not shown. and a decrease
in p24 levels Ž Fig. 6. .
To determine whether the modest inhibitory effect
observed at 5 m M lipid concentration was sequencespecific, differentiated THP-1rHIV-1 IIIB cells were
exposed to 5 m M Lipofectin or DOTAP complexed
with the functional Rz, or with control MRz ŽTable
1.. When cells were treated for 24-h with free Rz at
5.5 m grml Ž0.44 m M., the p24 level was reduced by
30.7% compared to untreated controls Ž p F 0.005..
Under the same conditions MRz was not inhibitory.
However, both Rz and MRz were equally inhibitory
when they were complexed with cationic liposomes.
For example, Lipofectin complexed with Rz or MRz
at a ratio of 8:1 reduced the p24 levels by 30%
Ž p F 0.005.. Under the same conditions DOTAP
complexed with Rz or MRz reduced the p24 levels
by 34.5% Ž p F 0.0005. or 28.5% Ž p F 0.005., respectively.
Interestingly, the charge ratios Žqry . for the 8:1
and 4:1 complexes are 1.8 and 0.9, respectively.
Thus, it appears that the functional delivery of Rz in
the 4:1 complex is not dependent on the presence of a
net positive charge on the complex. However, it is
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Table 1
Effect of LF and DOTAP complexed with anti-LTR or MRz on p24 production in differentiated THP-1rHIV-1 IIIB cells a
Treatment

p24 Žngrml.
Free Rz

None
Anti-LTR Rz
MRz

3.68 " 0.43
2.55 " 0.14
3.81 " 0.36

LF:Rz
b

DOTAP:Rz

8:1

4:1

8:1

4:1

y
2.58 " 0.23
2.54 " 0.09

y
3.15 " 0.23
2.69 " 0.27

y
2.41 " 0.05
2.63 " 0.11

y
2.21 " 0.23
3.11 " 0.17

a

PMA-treated THP-1rHIV-1 IIIB cells, 6 days post-differentiation, were exposed to the liposome–Rz complexes, at lipid:Rz ratios Žwrw.
of 8:1 or 4:1 Ž0.93 and 1.9 m g Rzrml Ž0.074 and 0.15 m M., respectively., or the Rz alone at 5.5 m grml Ž0.44 m M., for 24 h. The p24
production within the previous 48-h period was measured on day 2. Data represent the mean " standard deviation of p24 determinations
in duplicate, in supernatants of duplicate wells Ž n s 4., except in controls which were measured in three wells.
b
Untreated controls.

possible that positively charged regions of the complexes mediate their attachment to the cells.
3.3. DeliÕery of liposome–Rz complexes to chronically infected HeLa r LAV cells
Chronically infected HeLarLAV cells were exposed to Lipofectin at 5, 10 and 15 m M, complexed
with Rz, at a lipid:Rz Žwrw. ratio of 8:1 or 4:1 in
DME medium with 8% FBS. Micrographs were taken
following a 4-h treatment at 378C. The cells were
further incubated and fed every day with fresh
DMEr10 medium; p24 production was measured on
days 1, 2 and 3. Although a concentration-dependent,
cell-associated diffuse fluorescence was observed, the
treatment did not affect p24 production, nor did it
cause cytotoxicity Ždata not shown. .

Lipofectin at 5, 10 and 15 m M, complexed with Rz,
at a lipid:Rz Ž wrw. ratio of 4:1 for 4 h in RPMI
medium with 8% FBS. On 1 and 2 days post-treatment, the culture medium was replaced with fresh
medium, and 3 days later the culture supernatants
were analyzed for viral p24. Under these conditions
treatment of de novo infected HeLa CD4q cells with
the Lipofectin–Rz complexes was cytotoxic while the
Rz alone was not toxic ŽFig. 7.. A similar cytotoxic
effect was observed when uninfected HeLa CD4q

3.4. DeliÕery of liposome–Rz complexes to de noÕoinfected HeLa CD4 qcells
One explanation for the lack of inhibition of p24
production in HeLarLAV cells by liposome–Rz
complexes is that the efficiency of delivery was too
low to affect significantly the level of p24 antigen in
culture supernatants of cells producing high quantities of virus. Therefore, we next examined if p24
production could be reduced by Lipofectin–Rz complexes in de novo infected HeLa CD4q cells, producing much lower levels of virus.
HeLa CD4q cells were infected with HIV-1 IIIB at
5 = 10 3 TCID50 per well, as described in Section 2.
Immediately after infection the cells were exposed to

Fig. 7. Effect of LF complexed with Rz on p24 production in de
novo infected HeLa CD4q cells. The cells were exposed to the
LF–Rz complexes at a lipid:Rz ratio Žwrw. of 4:1, or to the Rz
alone at 5.5 m grml Ž0.44 m M., for 4 h Žsee Section 2 for
details.. The p24 antigen production within the previous 72-h
period was measured on day 5 and was expressed as percent of
the control Ž100%s 0.56"0.11 ng p24rml.. Cell viability was
measured on day 5 post-infection Žincubation with Alamar Blue
for 90 min at 378C. and was expressed as percent of the control.
Data represent the mean"standard deviation obtained from duplicate wells or quadruplicate control wells.
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cells were incubated with the Lipofectin–Rz complexes Ždata not shown..

4. Discussion
Our results demonstrate that Ži. treatment with
liposome–Rz complexes results in cell-associated fluorescence in a concentration-dependent manner; Žii.
different cellular fluorescence patterns are observed
with the four cationic liposomal preparations Ž Lipofectamine, Lipofectin, DMRIE and DOTAP. ; Ž iii.
treatment of THP-1rHIV-1 IIIB cells with both functionally active or MRz complexed with 5 m M Lipofectin or DOTAP for a 24-h period causes a reduction
in HIV production; Živ. differentiated chronically infected THP-1rHIV-1 IIIB cells are more susceptible to
killing by liposome–Rz complexes than uninfected
THP-1 cells; Žv. CD4-expressing HeLa cells are more
susceptible to killing by liposome–Rz complexes than
chronically infected HeLarLAV cells.
Compared to the wide variety of methods used to
deliver DNA, progress in introducing RNA molecules
into cells has been slow, probably because of the
rapid degradation of RNA by both exo- and endoribonucleases w24x. Only a few studies have reported
results obtained with exogenous delivery of Rz. In
one study polybrene-treated H9 cells were incubated
with 1 or 100 m M anti-HIV-1 gag Rz and subsequently infected with HIV-1 w45x. The formation of
syncytia was assessed 7 days after infection. The Rz
inhibited the formation of syncytia by 9% and 67%,
at 1 and 100 m M, respectively, when compared to
untreated controls. These results suggest that the
exogenous administration of anti-HIV-1 Rz may be
effective in blocking viral infection in H9 cells.
However, the pre-formed Rz RNAs were short-lived,
and 5 h after addition no intact Rz RNAs could be
detected inside the cells. In a subsequent study, the
anti-HIV-1 gag Rz Ž142 nucleotides in length. was
encapsulated in liposomes composed of 50 mol%
dipalmitoylphosphatidylglycerol. This procedure enhanced the uptake and protected the RNA molecules
from degradation over a 48-h period in H9 cells w2x.
Similarly, encapsulation of an all-RNA Rz in liposomes containing dimyristoylphosphatidylglycerol
ŽDMPG. , phosphatidylethanolamine and cholesterol,
or cardiolipin, phosphatidylcholine and cholesterol
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increased its resistance to serum ribonucleases for at
least 24 h and enhanced the accumulation of Rz in
HepG2 cells to up to 1.5% of the added dose after 24
h w30x.
Cationic liposomes as an exogenous delivery system for Rz have likewise been described in only a
few studies. In one study chimeric DNA–RNA Rz
complexed with Lipofectin were shown to be more
stable in H9 cells over a 48-h period than their
all-RNA counterparts w19x. Lipofectin was also used
to deliver hammerhead Rz targeted to human urokinase receptor mRNA, into human osteosarcoma cells
w46x. While free Rz were degraded immediately in
medium, Rz complexed with Lipofectin were stable
for up to 22 h and were efficiently transported into
the cytoplasm. Another cationic liposome formulation, Transfectam Ž lipopolyamine. , was used to deliver a chimeric hammerhead Rz directed against
bcr-abl mRNA, to a cell line ŽEM-2. derived from a
patient with chronic myelogenous leukemia w47x. The
Rz decreased the level of bcr-abl mRNA and inhibited expression of the bcr-abl gene product, as well
as cell growth. A multi-unit Rz that targets bcr-abl
mRNA was delivered into murine myoloblasts transformed with the bcr-abl gene Ž32D cells., using
either Lipofectin or folic acid–polylysine w48x. Both
delivery systems protected Rz from degradation in
serum-free-medium up to 24 h and enhanced Rz
uptake; however, the folate receptor-mediated uptake
was up to 10-fold more efficient than that mediated
by Lipofectin. Another cationic lipid, DOTAP, was
used to deliver hammerhead Rz targeted to the MDR1 mRNA, into human pleural mesothelioma cells
w49x. A 42-mer chimeric DNA–RNA hammerhead Rz
targeted to a leukocyte-type 12-lipoxygenase mRNA,
was delivered into porcine aortic vascular smooth
muscle cells after complexation with Transfectam
w50x. The Rz almost completely inhibited specific
mRNA expression at 4 m M, but appeared to be
ineffective at 0.5 m M. We should note that the use of
Rz concentrations in the range 0.5–4 m M in our
experiments would have been toxic to the cells.
Our results indicate that cationic liposome–Rz
complexes are readily taken up by differentiated
THP-1rHIV-1 IIIB cells. However, in spite of the
intracellular accumulation of the Rz, its effect on
virus production is confined to a very limited set of
non-cytotoxic conditions. The lack of specific inhibi-
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tion by the liposome-complexed functional Rz vs. the
MRz may be explained by a non-specific oligonucleotide effect. In contrast, the free MRz did not
inhibit p24 production when compared with the free
functional Rz Ž Table 1. . Since the functionally active
chimeric Rz have been effective against cellular targets w19x, the lack of major efficacy against HIV is
most likely due to the inability of the Rz to enter the
cytoplasm in sufficient quantities to inhibit virus
production. It is also not clear what fraction of the Rz
is free to interact with substrate, and what fraction is
bound to cellular proteins or remain in the endocytotic pathway. It is also possible that cationic lipids
augment the production of nucleases which degrade
the Rz. Our results suggest that cationic liposome–Rz
complexes are sequestered in intracellular
membrane-bound compartments, such as endosomes,
similar to the fate of cationic liposome–DNA complexes w51x. Such sequestering, together with the low
efficiency of cytoplasmic delivery could diminish the
potential effectiveness of the Rz, especially in chronically infected cells producing high quantities of virus.
Although we have utilized four cationic liposome
formulations and two Rz:lipid ratios in our studies, it
is possible that a more extensive matrix of Rz and
lipid concentrations may enhance the cytoplasmic
delivery of exogeneous Rz.
It will be of interest to investigate whether endosome disrupting peptides, such as those used to enhance the expression of transferrinrpolylysine-complexed DNA w52x, or transferrin–cationic liposome
complexes w53x will facilitate the delivery of Rz into
the cytoplasm. We have shown that peptides that
interact with and destabilize membranes at mildly
acidic pH enhance gene delivery by cationic liposomes w54x. Likewise, the intracellular delivery of Rz
in pH-sensitive liposomes, which are thought to
destabilize the endosome membrane at the mildly
acidic pH of the endosome lumen w55,56x, may result
in enhanced cytoplasmic delivery. Preliminary experiments in our laboratory have shown that the Rz used
in this study is effective in inhibiting HIV production
by macrophages when delivered in pH-sensitive liposomes ŽN. Duzguneş,
E. Pretzer and S. Simoes,
¨ ¨
˜ unpublished data. . The recent development of sterically
stabilized pH-sensitive liposomes with a prolonged
circulation half-life w57x may render feasible the in
vivo delivery of Rz to target cells and tissues.

Differentiated THP-1rHIV-1 IIIB cells were more
sensitive to cytotoxic effects of liposome–Rz complexes than differentiated THP-1 cells. Interestingly,
the formation of complexes with Rz significantly
changes the toxic effect of liposomes alone. For
example, a 4-h treatment of differentiated THP-1
cells with the Lipofectamine–Rz complex at 8 m M
lipid caused a decrease in cell viability Ž Fig. 3. , while
8 m M Lipofectamine alone was not toxic even after a
24-h treatment w39x. HeLa CD4q cells were more
susceptible to cytotoxic effects of liposome–Rz complexes than uninfected THP-1 cells, chronically infected THP-1rHIV-1 IIIB cells or HeLarLAV cells.
These data are consistent with previous observations
that both the efficiency of cationic lipid-mediated
transfection and the toxicity of lipids or lipid–DNA
com plexes, vary for different cell types
w20,24,26,51,58,59x.
In summary our results indicate that the effective
delivery of functional Rz into cells by cationic liposomes is an inefficient process and needs extensive
improvement before the technique can be used successfully in ex vivo and in vivo applications. Viral
targets such as HIV, especially in chronically infected
cells, may not be as well suited for exogenous Rz
delivery as are intracellular targets present in smaller
molar amounts. It is possible that delivery of gene
constructs for continuous endogenous expression of
the Rz is a more promising strategy.
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